FDA Inspection 1165965 — Hakim Charfi
The FDA completed an inspection of Hakim Charfi on February 25, 2022 in Rennes Cedex. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 25, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Rennes Cedex (France)
Additional Details
Clinical BA/BE